SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company today announced the detailed results of ACHIEVE-3, the first Phase 3 head-to-head study that assessed the safety and effectiveness of orforglipron, a small agonist oral molecule of the GLP-1 receptor without restrictions regarding food or water, compared to oral semaglutide in adults with type 2 diabetes not properly controlled with methylformin. The study, lasting 52 weeks, enrolled 1.698 participants in four treatment groups: orforglipron 12 mg and 36 mg and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforglipron showed superiority compared to oral semaglutis on the primary endpoint and all key secondary endpoints, with significantly greater improvements than HbA1c and weight. The results were published today on The Lancet. “The results of ACHIEVE-3 highlight the potential benefits of orphorglypron compared to oral semaglutis in type 2: increased HbA1c reduction, increased weight loss and possibility of intake without time constraints compared to meals or water: a combination that can make a significant difference for people who manage their disease day by day – says Kenne Orforglipron has also shown clinically significant improvements compared to basal on key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure and triglycerides. “In direct comparison with oral semaglutis, the ACHIEVE 3 study demonstrated the superiority of the treatment on specific key endpoints, including the control of glycated hemoglobin and body weight reduction – says Stefano Del Prato, Affiliate Professor, Interdisciplinary Research Centre Health Science, Sant’Anna University School of Pisa -. These results confirm the potential of orforglipron as a new oral therapeutic option for treating adults with type 2 diabetes.” The overall safety and tolerance profile of orforglipron in ACHIEVE-3 was consistent with what was observed in previous studies. For orforglipron and oral semaglutide, the most common adverse events were nausea, diarrhea, vomiting, dyspepsia and appetite reduction. Treatment rates due to adverse events were 8.7% (12 mg) and 9.7% (36 mg) per orforglipron, compared to 4.5% (7 mg) and 4.9% (14 mg) per oral semaglutide. Lilly has presented orforglipron to regulatory authorities in over 40 countries; in the United States, the submission for type 2 diabetes is expected later this year.
– Lilly press office photos –(ITALPRESS).
